BACKGROUND: Enoxaparin is often diluted to accurately deliver doses to neonatal and infant patients. Current recommendations for dilutions may not be adequate for the smallest patients. METHODS: Review of dosing at our institution occurred, and an 8 mg/mL concentration of enoxaparin was chosen. A concentration of 8 mg/mL was compounded by diluting 0.4 mL of enoxaparin (100 mg/mL) into 4.6 mL of sterile water for injection into an empty sterile vial. Four syringes of the 8 mg/mL concentration were prepared by 5 technicians (20 total syringes). Stability and sterility testing occurred a 0, 7, 14, and 30 days. One-way repeated-measures analysis of variance was used to detect significant differences in Anti-Factor Xa concentrations at the testing time points. RESULTS: The dilution of enoxaparin was sterile at 30 days but exhibited significant degradation at the 30-day point (p < 0.05). CONCLUSION: A dilution of enoxaparin 8 mg/mL is stable and sterile for 14 days refrigerated but is not stable at 30 days.
BACKGROUND:Enoxaparin is often diluted to accurately deliver doses to neonatal and infantpatients. Current recommendations for dilutions may not be adequate for the smallest patients. METHODS: Review of dosing at our institution occurred, and an 8 mg/mL concentration of enoxaparin was chosen. A concentration of 8 mg/mL was compounded by diluting 0.4 mL of enoxaparin (100 mg/mL) into 4.6 mL of sterile water for injection into an empty sterile vial. Four syringes of the 8 mg/mL concentration were prepared by 5 technicians (20 total syringes). Stability and sterility testing occurred a 0, 7, 14, and 30 days. One-way repeated-measures analysis of variance was used to detect significant differences in Anti-Factor Xa concentrations at the testing time points. RESULTS: The dilution of enoxaparin was sterile at 30 days but exhibited significant degradation at the 30-day point (p < 0.05). CONCLUSION: A dilution of enoxaparin 8 mg/mL is stable and sterile for 14 days refrigerated but is not stable at 30 days.
Authors: S Hofmann; R Knoefler; N Lorenz; G Siegert; J Wendisch; D Mueller; H Taut-Sack; J Dinger; M Kabus Journal: Thromb Res Date: 2001-09-01 Impact factor: 3.944
Authors: Joan Sanchez de Toledo; Sriya Gunawardena; Ricardo Munoz; Richard Orr; Donald Berry; Sara Sonderman; Sara Krallman; Dana Shiderly; Li Wang; Peter Wearden; Victor O Morell; Constantinos Chrysostomou Journal: Cardiol Young Date: 2010-03-04 Impact factor: 1.093
Authors: D Dix; M Andrew; V Marzinotto; K Charpentier; S Bridge; P Monagle; G deVeber; M Leaker; A K Chan; M P Massicotte Journal: J Pediatr Date: 2000-04 Impact factor: 4.406
Authors: Janet I Malowany; David C Knoppert; Anthony K C Chan; Dion Pepelassis; David S C Lee Journal: Pharmacotherapy Date: 2007-09 Impact factor: 4.705
Authors: Mary E Bauman; Mark J Belletrutti; Laszlo Bajzar; Karina L Black; Stefan Kuhle; Michelle L Bauman; M Patricia Massicotte Journal: Thromb Haemost Date: 2009-01 Impact factor: 5.249